If Freenome Holdings Inc.’s $254 million funding round is a sign, the capital markets for med-tech may finally be thawing. The cancer diagnostics company’s latest cash infusion brings its total funds raised to date to more than $1.3 billion. Freenome co-founder and Chief Product Officer Riley Ennis told BioWorld the company’s success in raising cash in a challenging market was attributable to the “perfect storm of huge unmet need and the opportunity that we have, given the treatment advancements.”

Related Keywords

Riley Ennis , Freenome Holdings Inc , Freenome Holdings , Chief Product Officer Riley Ennis , Bioworld Medtech , Freenome Inc , Liquid Biopsy , Cancer Screening , Quest Diagnostics Inc , Roche Holding Ag , Oncology , Cancer , Efinancings , Us , Diagnostics ,